- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
AbCellera Biologics Inc. completed its initial public offering and its shares are now available on the Nasdaq under "ABCL." Vancouver-based AbCellera is an AI-powered drug discovery company working with Eli Lilly & Co. on a COVID-19 vaccine.
Our top picks for where to buy Abcellera Biologics Inc stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy AbCellera Biologics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ABCL. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy AbCellera Biologics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
AbCellera Biologics stock price (NASDAQ: ABCL)
Use our graph to track the performance of ABCL stocks over time.AbCellera Biologics shares at a glance
Information last updated 2024-12-19.
| Latest market close | $2.85 |
|---|---|
| 52-week range | $2.34 - $6.06 |
| 50-day moving average | $2.79 |
| 200-day moving average | $3.26 |
| Wall St. target price | $12.29 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.61 |
Is it a good time to buy AbCellera Biologics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
AbCellera Biologics price performance over time
Historical closes compared with the close of $2.85 from 2024-12-20
| 1 week (2024-12-12) | -3.39% |
|---|---|
| 1 month (2024-11-21) | 4.78% |
| 3 months (2024-09-20) | 10.04% |
| 6 months (2024-06-21) | -1.72% |
| 1 year (2023-12-21) | -49.91% |
|---|---|
| 2 years (2022-12-21) | -73.11% |
| 3 years (2021-12-21) | 15.74 |
| 5 years (2019-12-18) | N/A |
AbCellera Biologics financials
| Revenue TTM | $33 million |
|---|---|
| Gross profit TTM | $311.1 million |
| Return on assets TTM | -13.26% |
| Return on equity TTM | -15.55% |
| Profit margin | 0% |
| Book value | $3.65 |
| Market Capitalization | $794.5 million |
TTM: trailing 12 months
AbCellera Biologics share dividends
We're not expecting AbCellera Biologics to pay a dividend over the next 12 months.
You may also wish to consider:
AbCellera Biologics share price volatility
Over the last 12 months, AbCellera Biologics's shares have ranged in value from as little as $2.335 up to $6.055. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AbCellera Biologics's is 0.351. This would suggest that AbCellera Biologics's shares are less volatile than average (for this exchange).
To put AbCellera Biologics's beta into context you can compare it against those of similar companies.
- Genmab AS (GMAB.US): 0.859
- XBiotech (XBIT.US): 1.413
- Aridis Pharmaceuticals (ARDS.US): -26.035
AbCellera Biologics overview
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Frequently asked questions
nullWhat percentage of AbCellera Biologics is owned by insiders or institutions?
Currently 27.928% of AbCellera Biologics shares are held by insiders and 39.785% by institutions. How many people work for AbCellera Biologics?
Latest data suggests 586 work at AbCellera Biologics. When does the fiscal year end for AbCellera Biologics?
AbCellera Biologics's fiscal year ends in December. Where is AbCellera Biologics based?
AbCellera Biologics's address is: 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1 What is AbCellera Biologics's ISIN number?
AbCellera Biologics's international securities identification number is: CA00288U1066
More resources on Finder
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Sweep Accounts
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question